אוונקס ישראל - עברית - Ministry of Health

אוונקס

medison pharma ltd - interferon beta 1a 30 mcg/vial - powder for solution for injection - interferon beta-1a - avonex is indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. avonex is also indicated for the treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

אוונקס תמיסה להזרקה ישראל - עברית - Ministry of Health

אוונקס תמיסה להזרקה

medison pharma ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

מתוטרקסאט "אבווה" 10 מ"ג/מ"ל ישראל - עברית - Ministry of Health

מתוטרקסאט "אבווה" 10 מ"ג/מ"ל

pharmalogic ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. methotrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, methotrexate is indicated only in the

בייאטה 5 מק"ג ישראל - עברית - Ministry of Health

בייאטה 5 מק"ג

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

בייאטה 5 מק"ג ישראל - עברית - Ministry of Health

בייאטה 5 מק"ג

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

בייאטה 10 מק"ג ישראל - עברית - Ministry of Health

בייאטה 10 מק"ג

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

בייאטה 10 מק"ג ישראל - עברית - Ministry of Health

בייאטה 10 מק"ג

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

פגסיס 135 מק"ג/0.5 מ"ל ישראל - עברית - Ministry of Health

פגסיס 135 מק"ג/0.5 מ"ל

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 135 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

פגסיס 180 מק"ג/0.5 מ"ל ישראל - עברית - Ministry of Health

פגסיס 180 מק"ג/0.5 מ"ל

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 180 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

קרבופלטין "אבווה" 10 מ"ג/מ"ל ישראל - עברית - Ministry of Health

קרבופלטין "אבווה" 10 מ"ג/מ"ל

pharmalogic ltd - carboplatin 10 mg/ml - solution for infusion - carboplatin - carboplatin is used alone or in combination with other antineoplastic agents in the treatment of advanced ovarian carcinoma and metastatic small cell lung cancer.